Type 2 Diabetes

Type 2 diabetes, formerly called adult-onset or noninsulindependent diabetes, is the most common form of diabetes. People can develop type 2 diabetes at any age, even during childhood. This form of diabetes usually begins with insulin resistance, a condition in which fat, muscle, and liver cells do not use insulin properly. At first, the pancreas keeps up with the added demand by producing more insulin. In time, however, it loses the ability to secrete enough insulin in response to meals. People who are overweight and inactive are more likely to develop type 2 diabetes. Treatment includes taking diabetes medicines, making wise food choices, exercising regularly, controlling blood pressure and cholesterol, and taking aspirin daily—for some.

What is Type 2 Diabetes?

Type 2 diabetes is a common metabolic condition that develops when the body fails to produce enough insulin or when insulin fails to work properly, which is referred to as insulin resistance. Insulin is the hormone that stimulates cells to uptake glucose from the blood to use for energy.

Type 2 Diabetes Treatment

Insulin Medication

What is Insulin Resistance?

What is Diabetes?

Diabetes Mellitus Type 2 Pathophysiology

Type 2 Diabetes Symptoms

Fibromyalgia and Diabetes

Does the Keto Diet Increase the Risk of Diabetes?

Type 2 Diabetes Diagnosis

Vitamin D and Type 2 Diabetes

Type 2 Diabetes Screening and Prevention

See more featured articles »

Insulin Resistance Symptoms

Diabetes in Men versus Women

Insulin Resistance Treatment

Living With Type 2 Diabetes

Insulin Resistance Diagnosis

Insulin Resistance Pathophysiology

Are Low Carbohydrate Diets Good for Type 2 Diabetes?

Insulin Resistance and Parkinson's Disease

Causes of Insulin Resistance

The Risks of Prediabetes

Is a Plant-Based Diet Good for Type 2 Diabetes?

Latest Type 2 Diabetes News and Research

Survey reveals critical knowledge gaps in maternal health recommendations

Most Americans know that how well a mother takes care of herself before and during pregnancy affects the health of a baby, but many people remain unclear about some specific maternal health recommendations, including when to start avoiding alcohol, according to a new nationally representative survey from the Annenberg Public Policy Center (APPC) of the University of Pennsylvania.

29 May 2026

Gut microbes may reveal who is at risk of type 2 diabetes years before diagnosis

A large Swedish prospective cohort study found that specific gut microbial species and metabolic pathways measured years before diagnosis were associated with future type 2 diabetes risk. The findings suggest that gut microbiome composition and functional potential may help explain T2D development, but replication is needed before clinical use.

28 May 2026

How common spices may improve gut, brain, and metabolic health

The health effects of spices are explored, revealing their potential to influence blood sugar, inflammation, and brain function through various mechanisms.

28 May 2026

Scientists rethink GLP-1 delivery to improve dosing, tolerability, and adherence

The review highlights nanocarriers, microspheres, hydrogels, microneedles, long-acting formulations, and co-formulations as promising but mostly early-stage strategies that still require stronger long-term clinical evidence.

27 May 2026

Retatrutide reshapes metabolism in obesity and type 2 diabetes, study finds

Retatrutide altered circulating metabolites and lipids linked to fatty acid oxidation and insulin resistance in people with obesity, with or without type 2 diabetes. These biomarker changes suggest improved metabolic health, but the post-hoc analysis remains hypothesis-generating and does not prove direct clinical benefit.

26 May 2026

Complete 3D map of pancreas reveals surviving insulin cells

Researchers at Umeå University have conducted a unique three-dimensional mapping of an entire human pancreas.

26 May 2026

Hydroxychloroquine lowers heart risks in skin lupus patients

A study led by investigators from Johns Hopkins Medicine found that some patients with discoid lupus erythematosus - a form of skin lupus commonly diagnosed in young to middle-aged Black women that causes disc-shaped plaques to form on the body - were less likely to experience complications, such as diabetes, hypertension and coronary artery disease if they were prescribed hydroxychloroquine.

26 May 2026

Immunoproteasome plays emerging role in diabetes and metabolic complications

A newly published review article highlights the emerging importance of the immunoproteasome in the development and progression of diabetes and its wide-ranging complications, offering fresh perspectives on future therapeutic strategies.

24 May 2026

HonorHealth Research Institute tests steam therapy for diabetes treatment

HonorHealth Research Institute is looking to become the first research facility in the nation to begin a new clinical trial that aims to modify the lining of the digestive tract with the use of steam energy to control type II diabetes without the use of drugs.

21 May 2026

Elevated blood glucose during pregnancy signals a significantly higher future diabetic risk

Gestational diabetes is a strong risk factor for future type 2 diabetes, even in women with normal pre-pregnancy weight, according to a study at the University of Gothenburg. The researchers call for earlier testing and better follow-up.

21 May 2026

Oral AD109 improves sleep apnea severity but tolerability remains a challenge

AD109, an investigational once-daily oral combination of aroxybutynin and atomoxetine, significantly improved airway obstruction and oxygenation in adults with mild-to-severe obstructive sleep apnea who could not use PAP therapy. However, symptom improvements did not clearly differ from placebo, and about one in five AD109 recipients discontinued treatment due to adverse events.

21 May 2026

GLP-1 drugs may help curb addiction by targeting reward pathways

GLP-1 receptor agonists, already used for Type 2 diabetes and obesity, show promise in reducing alcohol and drug-seeking behaviors through central reward and dopamine-related pathways. Most evidence remains preclinical, with limited early human data, so larger clinical trials are needed before these drugs can be recommended for addiction treatment.

21 May 2026

New AI framework maps systemic obesity damage at cellular resolution

Researchers at Helmholtz Munich, the Ludwig Maximilians University Munich (LMU) and collaborating institutions have developed an artificial intelligence (AI) framework that maps disease-related changes throughout the entire mouse body at cellular resolution.

20 May 2026

Researchers uncover new genetic links influencing blood lipid composition

DZNE researchers have generated new insights into how the human genome shapes the chemical composition and concentration of blood lipids.

20 May 2026

Global consortium renames polycystic ovary syndrome to reflect science

First, it was named after two men. Then, it was named for a false premise. Now, after more than a century, one of the most common hormone disorders affecting women worldwide has a name that reflects the science.

18 May 2026

Integrated care needed for lifelong Polyendocrine Ovarian Syndrome management

Polycystic Ovary Syndrome, which has just been renamed Polyendocrine Ovarian Syndrome (PMOS), is the most common hormonal and metabolic disorder affecting women of reproductive age, impacting up to 13% of this population and contributing to nearly 40% of infertility cases worldwide.

18 May 2026

Once-nightly oral pill helps control obstructive sleep apnea

A once-nightly oral pill helped control obstructive sleep apnea in a large, phase 3 clinical trial presented at the 2026 ATS International Conference.

18 May 2026

Olive waste extract may help lower fat and improve muscle markers

A polyphenol-rich olive oil byproduct may enhance muscle health, reducing fat mass and improving antioxidant markers in adults with metabolic risk factors.

18 May 2026

GLP-1 weight loss medications linked to significant drop in asthma flares

New research presented at this year's European Congress on Obesity in Istanbul, Turkey (12-15 May) shows the use of the new GLP-1 class of obesity drugs in people with asthma is associated with a 26 % fall in the number of asthma exacerbations and a 14% drop in use of asthma inhaler reliever use. The study is by Simon Høj and Dr Kjell Erik Julius Håkansson, Copenhagen University Hospital, Copenhagen, Denmark and colleagues.

15 May 2026

New obesity medications offer a potent tool for combating hypertension

A meta-analysis of 32 studies and 43,618 adults presented at this year's European Congress on Obesity in Istanbul, Turkey (12-15 May) shows that use of new classes of obesity drugs for weight loss is associated with a clinically relevant drop in blood pressure (BP): a 0.34 mmHg reduction in systolic BP per 1\% weight loss.

15 May 2026